Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Study Overview
=================
Brief Summary
-----------------
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.

Detailed Description
-----------------
In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tree and/or grass pollen induced pollinosis and/or asthma will be analyzed. In addition, the change in medication usage, asthma status for asthmatic patients after 3, 4 or 5 years of allergen specific immunotherapy will be evaluated. Furthermore, patients will be asked for their change in quality of life after therapy end.

Official Title
-----------------
Retrospective Data Collection Based on Patient Records and Questionaire Based Data of Therapy Results of Allergen-specific Immunotherapy With Pollinex Quattro With Tree and/or Gras Pollen Extracts and Their Mixtures

Conditions
-----------------
Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma, Allergic Conjunctivitis

Intervention / Treatment
-----------------
* Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 years Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grass and/or tree pollen completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts or their mixtures according to SMPC effective during immunotherapy Exclusion Criteria: Contraindication according to Summary of Product Characteristics (SMPC) effective during immunotherapy no additional allergen-specific immunotherapy with another product than Pollinex Quattro

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults<br>Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy | Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures<br>* retrospective analysis of patient records of allergen-specific immunotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in allergen specific IgE after allergen-specific immunotherapy | Efficacy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in medication usage after allergen-specific immunotherapy | Efficacy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | 
| Change in FEV1 (forced expiratory volume at one second; measured in %) after allergen-specific immunotherapy | Efficacy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | 
| Change in lung function resistance (measured in Kpa/l/s) after allergen-specific immunotherapy | Efficacy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | 
| Assessment of allergic eye symptoms (itching, tearing, redness, feeling of pressure) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | Efficacy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy | 
| Assessment of allergic nasal symptoms (rhinorrhea, nasal obstruction) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | Efficacy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy | 
| Assessment of allergic lung/bronchial symptoms (shortness of breath, cough), on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | Efficacy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy |